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Abstract 
Background: Outcomes after open esophagectomy (OE) have been shown to depend on 
institution case volume.  We aim to determine whether a similar relationship exists for minimally-
invasive esophagogastrectomy (MIE). 
Methods: Patients who had OE or MIE (excluding robotic procdures) between 2010 and 2013 
in the National Cancer Database were included. Outcomes included 30- and 90-day mortality, 
length-of-stay, hospital readmission, margin positivity, and number of lymph nodes harvested.  
Logistic and linear regression were used to adjust for possible confounders including age, 
gender, tumor size, Charlson score, induction therapy, and type of institution (academic vs. 
community-based).   
Results: We identified 2371 patients in the MIE group and 6285 patients in the OE group.  In 
multivariate analysis, high case volume was an independent predictor for lower 30-day, 90-day 
mortality, shorter length-of-stay, and higher rate of negative-margin resection in OE (P<0.001) 
but not MIE.  After quartile ranking of institutions based on volume, MIE outcomes were found to 
be better in institutions in the highest volume quartile compared to those in the lowest (p< 
0.0001).   
Conclusions: In this dataset, MIE postoperative outcomes, unlike OE, did not correlate with 
hospital case volume.  Volume-outcome relationships may be affected by surgical approach.  
The effect of case volume on long-term outcomes after MIE warrants further study. 
Word Count: 205  
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Esophageal carcinoma typically presents with locally-advanced or metastatic disease 
precluding surgical resection1-4. For early-stage tumors, esophagogastrectomy (EG) is the best 
option for cure despite carrying significant risks and post-operative complications compared to 
other operations with similar complexity1,2,4.  Within the past decade, minimally-invasive (MIE) 
esophagogastrectomy has gained increasing popularity due to decreased post-operative pain 
and lengt-of-stay while maintaining similar outcomes when compared to the traditional open 
approach5-22. However, MIE has an extensive learning curve, and typically are performed 
routinely only at tertiary referral centers with high-volume15-19.  While previous reports indicated 
a direct correlation between open EG case volume and operative outcome20-28, no studies have 
evaluated this relationship in MIE.  The primary goal of this study is to determine whether short-
term and oncologic outcomes for minimally-invasive esophagogastrectomy for esophageal 
cancer is dependent on institutional case volume. 
Patients and Methods 
Patients 
The National Cancer Database (NCDB) is a de-identified clinical oncology hospital 
registry data from community, comprehensive community, and academic facilities.  Following an 
exemption granted by the local Institutional Review Board, the NCDB was queried for all 
esophagectomies performed between January 1 2010 through December 31, 2013.  We elected 
to begin with 2010 and not earlier due to the minimal implementation of MIE prior to this time 
period.  We chose to end data collection at 2013 to allow for a complete 5-year follow-up in our 
analyses.  Patients with concurrent laryngectomy, esophagogastrectomy with staged or non-
gastric conduits were excluded.  All included patients were categorized into laparoscopic (MIE), 
open (OE), or robotic.  Given the small number of robotic esophagectomies, this group was 
excluded from final analysis.   
Statistical Analysis 
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Demographics including age and gender, Charlson comorbidity index, neoadjuvant 
chemoradiation, clinical, and pathological T-stage were described using descriptive statistics.  
Pearson’s Chi-square and student’s t-tests were used to analyzed categorical and continuous 
variables, respectively.  Pooled multivariable logistic  and linear models were used to examine 
outcomes including 30 and 90-day mortality, R0 resection, 30-day readmissions, long-term 
survival, length-of-stay, number of regional nodes collected, and number of positive nodes.  All 
models were controlled for the effect of annual case volume and annual laparoscopic-to-open 
conversion rates in addition to preoperatibe characteristics.  Multicollinearity were tested and 
highly correlative variables were omitted from our final model28.  Casewise deletion was used for 
missing data.  Multivariable regression analysis were performed for MIE and OE subgroup. 
Volume analysis 
The institution annual esophagogastrectomy (MIE and OE) case volume and MIE  case 
volume during the study period were analyzed.  Quartiles were created with cut-offs at 25th, 50th, 
and 75th percentile.  For each outcome, we performed interquartile comparisons of the 
multivariable regression estimates.  
Propensity Score Matching 
To examine any differences in outcomes between MIE and OE that might explain 
differences in volume-outcome realtionships due to selection bias29, we used PSMATCH230 
command in Stata SE 14.2 to match each MIE to OE case without replacement.  The optimal 
caliper width31 of 0.10 to match age, gender, tumor size, Charlson’s comorbidity score, induction 
radiation and chemotherapy, and type of institution (academic versus community-based). 
Multivariable logistic and linear regressions were performed on the matched pairs. 
Kaplan-Meier survival analysis 
Using time from diagnosis to the last contact and/or death, we performed Kaplan-Meier 
(KM) analysis to estimate the survival function for unmatched and matched cohorts. Difference 
in survival between MIE and OE were examined using log-rank tests.  
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Results 
We identifiied 8656 cases of esophagogastrectomy performed between January 1, 2010 
through December 31, 2013.  6285 cases were performed open and 2371 cases were 
performed using the minimally-invasive approach.  The median volume of 
esophagogastrectomy performed per year per facility was 8 (range 1-113).  Similarly, the 
median volume of MIE performed per facility was 5 (range 1-42) with a mean conversion rate of 
3.3 cases per year.  
Cohorts 
Demographics and preoperative factors including tumor size, Charlson score, clinical 
and pathologic staging, and neoadjuvant chemotherapy and radiation are presented in Table 1.  
There was no differences in any of the aforementioned factors except for larger tumor size (35 
mm versus 31 mm, p<0.05) and higher clinical T-stage (p<0.006) in OE.  No differences in 
pathologic staging were noted.  In bivariate analysis, the MIE group was noted to have a shorter 
length-of-stay (LOS) (p<0.001), lower 30-day and 90-day mortality (p<0.05), higher number of 
lymph nodes collected (p< 0.001), and longer 5-year overall survival (p<0.05) as compared to 
the OE cohort (Table 2).  Multivariate regression analyses identified the MIE approach as an 
independent predictor of lower 30 and 90-day mortality, shorter LOS, higher number of 
examined lymph nodes and higher 5-year survival (p<0.05) (Table 3).   These findings persisted 
after propensity matching was performed accounting for age, gender, Charlson Comorbidity 
Index, tumor size, and stage (p<0.05) (Table 4).  
 When looking at all cases (open and MIE), multivariate analysis revealed that volume 
was found to be a predictor of all outcome variables except for 30-day readmission (Table 3).  
Further subgroup analyses indicated that case volume as a continuous variable was a 
significant predictor of all outcome measures for OE but not MIE (Supplemental Table 1).  
Conversion from MIE to open approach was associated with a slight increased in 30-day 
mortality in MIE subgroup but carried no effects on any other outcomes. 
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Volume quartile analysis.  
Institutions were ranked based on the number of total esophagogastrectomy performed 
annually.  The lowest quartile performed an average of 2.4 cases annually and the highest 
quartile performed an average of 42.5 cases per year (range 20-113 cases). Regression 
estimates were compared between all quartiles (Table 5).  The highest performing centers were 
found to have reduced 30-day [OR 0.44] and 90-day [OR 0.56] mortality when compared to the 
two lowest-performing quartiles (p<0.05).  Centers that performed 20 to 113 cases per year (4th 
quartile) also had shorter length-of-stay [OR -1.80, p<0.05], higher number of lymph nodes 
collected [OR 6.09, p<0.001], and lower rate of incomplete resection [OR 0.63, p<0.05] when 
compared to the first quartile (p< 0.05).  High-volume centers have decreased long-term 
mortality compared to all other quartiles (p<0.05) (Table 5).  These differences dissipated when 
institutions were ranked based on annual MIE cases (Supplemental Table 2).  Similar analyses 
were performed for matched cohorts and no significant differences were noted for any outcome 
variables except for the number of lymph nodes collected and long-term mortality (data not 
shown). 
Oncologic outcomes 
Case volume and MIE were positive independent predictors of the number of lymph 
nodes collected in both matched and unmatched cohorts (Table 3, 4).  Although no differences 
were found in final N-stage in pooled results, subgroup analyses revealed that case volume 
correlates with higher rate of R0 resection and number of collected and lymph nodes in OE but 
not MIE (Supplemental Table 1).  Interquartile comparisons revealed similar findings. 
Comment 
Analyses of the Medicare database in 2011 indicated that EG operative complications 
are inversely associated with institutional case volume and thus shifted the paradigm towards 
centralizing care for esophagogastrectomy20,21,32.  A similar relationship was recently noted 
between complex laparoscopic operations and the volume of their open counterparts and 
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suggested institutionally-derived benefits at tertiary care centers32,33. In the setting of rapid 
adoption of minimally-invasive esophagectomies across all institutions, we seek to define the 
effects of esophagogastrectomy case volume on MIE outcomes. 
The NCDB database provided a robust multi-institutional patient population capturing 
approximately 75 percent of cancer cases in the United states with data regarding type of 
operations, type of institutions, and case volume over several years.  Our study of this patient 
population corroborated findings from previous reports indicating that volume is an independent 
predictor of postoperative outcomes and mortality in all esophagectomy cases22-27.  However, 
subgroup analysis suggest that this relationship only holds true for open cases and volume as a 
continuous variable did not contribute an effect on minimally-invasive esophagectomy.  We 
further explored this relationship in a volume-outcome relationships were analyzed as a rank-
test.  Our quartile analysis suggested that differences in outcomes are only seen between the 
highest (4th quartile) and lowest (1st quartile) volume centers.  This suggests that marginal 
increases in volume is not a positive predictor of outcome and corroborates with the finding of a 
large challenging learning curve of MIE in that a threshold case volume is required to achieve a 
benefit in outcome34,35,36.  Previous studies determined that mortality benefits arise from high-
volume centers that perform at least 20 esophagogastrectomies annually as compared low-
volume institutions perform between 1 to 10 cases34,35.  These divisions correlated with our 
quartile rankings.  Even though our analysis did not determine a cut-off value for the number of 
cases required to improve outcome, it is reasonable to surmise rankings similar to previous 
study.  It is interesting to note that differences in outcomes are only noted when institutions were 
ranked based on total volume of esophagectomy cases (open and MI) performed per year.  
When institutions were ranked based only on the number of MI esophagectomies performed 
annually, no significant differences were detected in any outcome parameters.  These results 
suggest that outcomes for MIE rely on institutionally-derived benefits including multidisciplinary 
care rather than on MIE case volume alone.  It is unclear at this point how and to what degree 
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the institutional advantages have conferred to these cases and this needs to be explored in 
future studies36,37.   
Our Kaplain-Meier analysis revealed a long-term survival benefit for MIE patients in 
matched cohorts with case volume as a significant predictor.  This is independent of 
preoperative clinical staging, surgical margins, complete resection, lymph node status, and final 
pathology staging.  To our knowledge, this survival advantage has not been previously 
established. Of interest, the number of resected lymph nodes correlated with higher case 
volumes and was also higher in MIE cases. These effects of institutional case volume on long-
term survival warrant further study.    
Our study is limited in its retrospective nature and data errors inherent to national 
databases exist.  In addition, the NCDB database also had missing data in several fields 
including clinical staging, pathology, and accurate description of surgical procedure type.  The 
missingness of our clinical staging was approximately 2.30%.  There were 2.59% (n=224) 
patients with missing pathological stages.  To address this, as suggested in the NCDB Public 
Use File Data Dictionary, we used clinical stage to impute the tumor staging.  After this 
imputation, we had only 2.26% (n=196) patients with missing stages.  Because of the small 
percent of missingness, casewise deletion was done when analyzing the pathological stages.  
In addition, we do believe that propensity matching eliminates these errors.  Another inherent 
limitation lies in the ability to determining volume association with specific complications of 
esophagogastrectomy including anastomotic leak.  Even though these surgery-specific 
outcomes were not captured in our dataset, it is assumed that their presence would indirectly 
prolonged LOS or increased 30-day readmission rate38.  We found that the MIE approach was a 
negative predictor of hospital LOS but that was negated in matched cohorts (p=0.051).  
However, no inferences can be made whether this is due to an equal rate of surgery-specific 
complications or secondary to the institutions’ abilities to mitigate the complications so that 
surrogate outcomes such as LOS and readmission are not affected.  The latter would suggest 
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that case volume have an indirect positive effect on shortening hospital stay but our findings on 
this were inconclusive.  Our study was also unable to account for specific surgical techniques 
(Ivor Lewis versus McKeown versus transhiatal), transfusions, and operative time which are 
factors that may mitigate surgical outcomes38.  However, we do believe that despite these 
limitations, these statistical reviews of NCDB still has value in defining certain, though not all, 
factors that contribute to overall outcomes of complex surgical procedures such as 
esophagectomy33,39.  
In conclusion, our analyses of the NCDB esophagogastrectomy database demonstrates 
that  perioperative outcomes  of open cases had a direct linear correlation with case volume.  
The effect of case volume on the MIE outcomes, however,  was only apparent when comparing 
the highest and lowest volume centers.  This may be due to the fact that small incremental 
changes in MIE volume do not confer any short-term advantages, particulary since the overall 
MIE outcomes were shown to be better in a parallel, propensity-matched analysis.  It is unclear 
whether the volume outcome relationships also confer a true long-term oncologic benefit.  
Further studies to investigate these relationships are warranted. 
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Table 1: Demographics 
 
 Unmatched Cohorts Matched Cohorts 
MIE [N=2371] OE [N=6285] MIE [ N=1819] OE [N=1819] 
Case volume/institution/year, 
       Mean(SD) 8.04 (8.69) 11.71 (14.29) 
 
8.15 (8.77) 
 
5.02 (5.86) 
Median (range)b 5 (1-42) 6 (1-71) 5 (1-42) 9 (1-28) 
Age, mean (SD) 63.43 (9.49) 63.11 (9.74) 63.67 (9.66) 63.35 (9.51) 
Gender, n(%)   
Male 1982 (27.75) 5161 (72.25) 1507 (82.85) 1537 (84.50) 
Female 389 (25.71) 1124 (74.29) 312 (17.15) 282 (15.50) 
Tumor size, mean (SD)a 36.78 (25.05) 38.15 (25.41) 36.88 (25.14) 37.57 (25.4) 
Median (range)a,c 31 (0-160) 35 (0-190) 32 (0-160) 33 (0-160) 
Charlson score, n(%)   
None 1667 (70.31) 4457 (70.91) 1277 (70.20) 1287 (70.75) 
1 557 (23.49) 1463 (23.28) 435 (23.91) 425 (23.36) 
>/=2 147 (6.2) 365 (5.81) 107 (5.88) 107 (5.88) 
Clinical Stage, n(%)a   
TIS  53 (2.27) 113 (1.85) 32 (1.78) 20 (1.12) 
T1 477 (20.39) 1099 (17.96) 378 (21.05) 334 (18.79) 
T2 440 (18.81) 1127 (18.42) 362 (20.16) 334 (18.79) 
T3 1094 (46.77) 2896 (47.34) 809 (45.04) 846 (47.58) 
T4 38 (1.62) 138 (2.26) 26 (1.45) 34 (1.91) 
Pathological Stage, n(%)   
0 137 (5.90) 319 (5.20) 80 (4.48) 73 (4.05) 
1 754 (32.46) 1827 (29.77) 591 (33.07) 549 (30.48) 
2 705 (30.35) 1957 (31.89) 547 (30.61) 595 (33.04) 
3 689 (29.66) 1913 (31.17) 542 (30.33) 545 (30.26) 
4 38 (1.64) 121 (1.97) 27 (1.51) 39 (2.17) 
Radiation, n(%)   
None 856 (36.1) 2210 (35.16) 709 (38.98) 650 (35.73) 
Neoadjuvant 1395 (58.84) 3681 (58.57) 1013 (55.69) 1054 (57.94) 
Adjuvant 97 (4.09) 328 (5.22) 87 (4.78) 102 (5.61) 
Chemotherapy, n(%)   
None 720 (30.37) 1805 (28.72) 581 (31.94) 535 (29.41) 
Neoadjuvant 1382 (58.29) 3750 (59.67) 1015 (55.80) 1066 (58.60) 
Adjuvant 129 (5.44) 398 (6.33) 115 (6.32) 127 (6.98) 
MIE conversion, rates/year(SD) 3.3 (8.88) 
 
2.29 (5.78) 
 
  MIE – minimally-invasive esophagectomy, OE- open esophagectomy 
a
 Statistically significant for unmatched group 
b
- non-parametric sign test, c- Kruskal-Wallis rank test 
All comparisons for matched cohorts are not statistically significan
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Table 2: Bivariate outcomes 
 
Full Cohort 
[N = 8656] 
MIE 
[N=2371] 
OE 
[N=6285] 
p-
value 
30-day mortality, n(%)a 335 (3.89) 73 (3.09) 262 (4.19) 0.018 
90-day mortality, n(%) 720 (8.46) 175 (7.49) 545 (8.84) 0.046 
Length-of-stay, mean (SD)a 14.37 (12.06) 13.61 (11.33) 14.67 (12.32) 0.0005 
30-day unplanned readmission, n(%) 705 (8.2) 184 (7.79) 521 (8.35) 0.399 
R0 resection, n(%) 7873 (92.91) 2202 (93.38) 5671 (92.75) 0.289 
Collected LN, mean (SD)a 13.96 (9.67) 15.38 (9.92) 13.42 (9.52) <0.001 
Positive LN, mean (SD) 1.18 (2.83) 1.13 (2.68) 1.2 (2.88) 0.3397 
5-year overall survival, n(%)a 4792 (55.36) 1374 (57.95) 3418 (54.38) 0.003 
 
a
 Significant difference 
MIE – minimally-invasive esophagogastrectomy 
LN – lymph node 
OE – open esophagogastrectomy
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Table 3: Regression analysis of unmatched cohorts  
 
30-day 
mortality* 
90-day 
mortality* 
Length of 
stay⧧ 
Positive 
Margin* 
LN 
collected⧧ 
LN 
positive⧧ 
30-day 
readmission* 
5-year 
mortality* 
Minimally-invasive 
esophagectomy 0.68a 0.83 -1.01a 0.98 1.58a -0.04 0.92 0.89 
Case volume 0.99a 0.99a -0.03a 0.99a 0.11a 0.01a 1.00 0.99a 
Age 1.05a 1.05a 0.04a 1.01a -0.02 -0.01a 1.01 1.02a 
Female 1.14 0.99 0.09 1.18 -0.28 -0.16 1.16 0.87a 
Tumor size 1.00 1.01a 0.01a 1.01a 0.01a 0.01a 1.00 1.01a 
Charlson score 
1 1.01 1.11 0.84a 0.99 0.02 0.05 1.39a 1.12 
>/=2 1.97a 1.45a 1.47a 0.96 -0.09 0.01 1.35 1.33a 
Pathological Stage  
1 0.75 0.82 0.16 1.16 0.67 -0.53a 1.62 1.21 
2 0.99 1.06 0.68 3.87a 1.50a 0.02 1.37 2.53a 
3 0.90 1.21 0.74 8.09a 2.97a 2.60a 1.41 4.31a 
4 1.85 3.59a 0.70 11.39a 1.42 3.04a 3.05a 6.57a 
Radiation  
Neoadjuvant 0.80 0.94 -2.20a 0.48a -1.59a -0.57a 0.92 1.14a 
Adjuvant 0.25a 0.29a -3.49a 2.18a -0.97 0.25 0.89 1.27a 
MIE-to-open conversionb 1.01 1.00 0.03 1.01 0.01 0.01 1.01 1.00 
 
 
a
 Significant difference (p<0.05) 
b
 Conversion rate/year 
LN- Lymph node 
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Table 4: Multivariable regression analysis of propensity-matched cohorts 
 
30-day 
mortality 
90-day 
mortality 
Length 
of stay 
Positive 
Margin 
LN 
collected 
LN 
positive 
30-day 
readmission 
5-year 
mortality 
Minimally-invasive 
esophagectomy 0.40a 0.63 a -0.98 0.98 2.95a 0.07 0.96 0.78a 
Case volume 1.01 1.00 0.00 0.99 0.11a 0.00 1.00 0.99a 
Age 1.06a 1.05a 0.02 1.01 -0.03 -0.01 1.02a 1.02a 
Female 1.00 0.90 0.59 0.70 -0.46 -0.25a 0.98 0.82 
Tumor size 1.00 1.01a 0.03a 1.01a 0.02a 0.00 1.00 1.01a 
Charlson score 
1 1.07 1.30 0.64 1.39 0.01 0.03 1.52a 1.20 
>/=2 2.22a 1.56 0.71 0.98 1.00 -0.05 1.44 1.52a 
Pathological Stage  
1 0.51 0.63 1.11 + 0.87 -0.29a 1.20 0.93 
2 0.66 0.84 1.47 + 1.54a 0.28a 0.86 1.97a 
3 0.67 0.85 1.84 + 2.97a 2.95a 0.89 3.80a 
4 1.04 1.12a 2.84 + 1.09 4.20a 1.81a 4.38a 
Radiation  
Neoadjuvant 0.96 1.08 -1.93a 0.47a -1.82a -0.44a 0.96 1.12 
Adjuvant 0.32 0.48 -2.99a 3.25a -1.77a 0.01 0.91 1.49a 
MIE-to-open conversionb   1.02 a 1.01 0.02 1.00 -0.03 0.00 1.00 1.00 
 
 
 
a
 Significant difference (p<0.05) 
b
 Conversion rate/year 
+ Could not determine statistically 
LN- Lymph node 
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Table 5: Outcomes of MIE after interquartile comparisons based on total annual esophagogastrectomy volume 
 
Dependent variable Quartiles AOR*/β-Coefficients⧧ p-value 
30-day mortality* 4 vs 1 0.44 <0.001 
4 vs 2 0.66 0.048 
4 vs 3 0.79 0.272 
90-day mortality* 4 vs 1 0.56 <0.001 
4 vs 2 0.78 0.077 
4 vs 3 0.88 0.383 
Length of stay⧧[days] 4 vs 1 -1.82 [13.55 vs. 15.56] <0.001 
4 vs 2 -0.78 [13.55 vs. 14.44] 0.086 
4 vs 3 -0.31 [13.55 vs 13.83] 0.474 
Positive Margin* 4 vs 1 0.63  0.001 
4 vs 2 0.86 0.316 
4 vs 3 1.10 0.551 
LN collected⧧ 4 vs 1 6.09 <0.001 
4 vs 2 3.71 <0.001 
4 vs 3 1.20 <0.001 
LN positive⧧ 4 vs 1 0.28 0.003 
4 vs 2 0.22 0.027 
4 vs 3 0.32 0.001 
30-day readmission* 4 vs 1 0.89 0.333 
4 vs 2 1.03 0.828 
4 vs 3 1.16 0.282 
5-year mortality* 4 vs 1 0.62 <0.001 
4 vs 2 0.68 <0.001 
4 vs 3 0.80 0.003 
 
AOR – Adjusted odds ratio, LN- Lymph node 
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Figure Legend 
Figure 1: Kaplan-Meier curve for propensity matched cohorts; MIE – minimally-invasive 
esophagogastrectomy; OE – open esophagogastrectomy 
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